GROWTH FACTOR PLPR PROCEDURE

Ovarian rejuvenation is a procedure which involves several steps. Hormone, immunologic and infective status is determined through blood tests. If the results are satisfactory, the procedure can be carried out.

The first step of PLRP is to obtain an adequate amount of blood, depending on the patient’s built and the assessed ovarian insufficiency, clinical picture, and prognosis, as well as the desired factor combination to be injected into the ovary.

  1. Separating platelet/thrombocyte-rich plasma (PRP) and platelet poor plasma is performed in a closed system – in a completely automatized machine designed for that purpose. This machine can process from 40ml to 180ml of the entire blood extracted from a patient. In sterile conditions, the Angel system obtains 18 times higher platelet concentration in PRP than the basic measured value in a patient. In our case, the optimum concentration is between 6 and 8 which we can be specified and set on the machine.
  2. Second stage or lab stage includes applying complex technology which, using special separators and systems, divides and filters specific cells, prepare them and activates the growth factors inside them. At the end of this procedure, we get between 5-7 mL of active plasma which contains a large amount of growth factors, among which PDGF (platelet-derived growth factor), TGF-beta (transforming growth factor beta), VEGF (vascular endothelial growth factor), FGF (fibroblast growth factor), EGF (epithelial growth factor), PDAF and PAF and many others.
  3. Preparation for the next phase includes measuring ovarian volume and vascularization, identifying indices which help us plan for the next stage.
  4. Next phase, installation, consists in color Doppler ultrasound-guided injection of the active substance, obtained from the patient’s own blood, into the ovarian tissue, free of blood vessels. This intervention is carried out 2 to 4 days from the onset of menstrual bleeding, under general or local anesthesia

POSSIBLE COMPLICATIONS
Possible complications are related to the injection of blood elements into the ovary. The complication rate is less than 1% and can involve bleeding, punctures or injuries to the surrounding organs and complication with anesthesia. Serious complications requiring hospital treatment are significantly less frequent.

TREATMENT EFFECTS
First results are to be expected in a few months and full effects are expected within 6 months. In the period following the treatment, standard in vitro fertility treatments are performed in a natural, modified and stimulated cycle. We track all changes in hormonal, immunological and reproductive parameters and closely follow and assess the results of the treatment.